= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Kostrzewa

MSACL 2018 EU Abstract

Topic: Microbiology

Podium Presentation in the Ether on Thursday at 14:50 (Chair: Stefan Zimmerman)

Sepsis by Enterobacteria: A MALDI Affair

Markus Kostrzewa (Presenter)
Bruker Daltonik GmbH

Presenter Bio(s): Study of biology at the Justus-Liebig-University, Giessen, Germany.

Diploma (1990) and Ph.D. thesis(1993) about molecular evolution of plastids.

1993 - 1997

Postdoc at the Institute of Human Genetics, JLU Giessen (AG Prof. U. Müller).

• Diagnostic of hereditary human diseases
• Research in the framework of the Human Genome Project

Joined Bruker in 1998

Head of the new R&D group “Bioanalytical Development“, establishment of molecular biology and biology related development at Bruker Daltonik.

Development of DNA analysis by MALDI-TOF mass spectrometry, “Clincal Proteomics” - methods, consumables and software for mass spectrometry profiling of body fluids and tissues

Development of microorganism identification by MALDI-TOF mass spectrometry (“MALDI Biotyper” system).

2005 Director Molecular Biology, R&D

2012 Vice President Clinical Mass Spectrometry R&D

2017 Vice President Microbiology & Diagnostics R&D

Heading the the microbiology and clinical research and development; application-, consumable-, and software- development. Strategic planning of innovative products in the field of clinical microbiology and diagnostics. Driving regulatory approval process (IVD-CE labelling, FDA clearance, ISO/AOAC certification for Food market)

Safety officer for medical products
More than 100 peer reviewed publications
Member of the German Society of Neurogenetics
Member of the German Society of Hygiene and Microbiology
Member of European Society of Clinical Microbiology
Member of the American Society for Microbiology

Authors: Markus Kostrzewa (1), Miriam Cordovana
(1) Bruker Dalltonik GmbH, Bremen, Germany (2) University Hospital Sant'Orsola-Malpighi, Bologna, Italy


Enterobacteria are the most frequent causative agents of sepsis. The spread of cephalosporinase- and carbapenemase-production in these species is a worrying threat for the effectiveness of the antibiotic therapy. Every hour saved in the detection of such strains can be crucial for the patients’ clinical outcome.

In this study, we investigate an innovative full MALDI-TOF MS based approach to quickly detect cephalosporinase- and carbapenemase-producing enterobacteria directly from the positive blood cultures bottles, applying the novel tools of the Biotyper system (Bruker Daltonik). The bacterial pellet extracted by Sepsityper was used for the species identification, for the detection of KPC-producing strains by subtyping, and for evaluation of cephalosporinase and carbapenemase activity by STAR-Cepha and STAR-Carba hydrolysis assays.

Financial Disclosure

Board Memberno
Stockyes Stocks and Options Bruker Corp
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: